The psychedelic mushrooms market is headed for a billion-dollar payday, according to a new market forecast report.
The Persistence Market Research report projects the global psychedelic mushrooms market will reach $3.3 billion by 2031. For comparison, the all-terrain vehicle or ATV market is predicted to reach that same value by 2030.
Currently, the psilocybin mushroom market is estimated at $1.5 billion. For the accounting nerds out there, Persistence predicts a whopping 10.3 percent CAGR for legal shrooms over a seven-year period. Compare that to the slightly cooler, but no less impressive, 8.3 percent CAGR for psilocybin from 2019 to 2023.
For those of you who don’t have finance degrees, those numbers mean the mushroom industry is expected to explode in the coming years. And that explosion will be carried by the movement’s usual drivers: regulatory reforms, academic research, and a growing consumer interest in psilocybin as a mental health treatment.
READ: AI Is Rapidly Changing Psychedelic Medicine, New Report Shows
The once-stigmatized psychedelic mushroom, particularly psilocybin, is undergoing a therapeutic renaissance. Its potential to treat mental health conditions such as depression, PTSD, anxiety, and addiction has garnered both scientific and public attention. Psilocybin’s ability to promote neuroplasticity, which may aid in brain regeneration, offers hope for conditions such as Alzheimer’s and Huntington’s disease. This, coupled with a growing wellness movement, has fueled demand for psilocybin-based products like teas, powders, and microdosing kits.
Regulatory changes are also driving market growth. Countries like the US, Canada, and the Netherlands are adopting more lenient policies toward psychedelic therapies. The report noted that this could lead to the reclassification of psilocybin for medical use or other exemptions for therapeutic purposes, opening doors for research and commercial ventures.
Public perception of psychedelics is shifting rapidly, too. As mental health concerns rise, so does the acceptance of alternative treatments like psilocybin therapy. Continued scientific validation of its efficacy will further fuel this shift. Recent surveys show more than 60 percent of American adults now support some form of regulated, legal psychedelic therapies.
However, significant challenges remain. Psilocybin’s classification as a Schedule I controlled substance imposes legal barriers on production, research, and distribution. Regulatory restrictions hinder large-scale studies that are crucial for broader medical validation.
READ: The VA Is Funding A Study to Determine If MDMA Can Really Treat PTSD
Despite potential risks, like hallucinations and anxiety, the industry is focused on innovation and standardization. Microdosing kits and user-friendly delivery mechanisms are making psilocybin therapy more accessible, too. Continued clinical research and successful trials are crucial to validate psilocybin’s therapeutic potential and pave the way for its mainstream adoption as a mental health treatment.
Ultimately, Persistence’s market report confirms the psychedelic mushrooms movement has made considerable progress over just the past few years. And their final piece of advice for biotech firms getting into the game: Adapt quickly to changing policies. Although current legal mushrooms markets do not follow the same retail model as legal cannabis, we saw that the most successful players in cannabis were the same ones with the capital, fortitude, and foresight to change with shifting regulations.
